文献速递肝病

肌肉减少症不恶化难治性腹水TIPSS患者生存

Sarcopenia Does Not Worsen Survival in Patients With Cirrhosis Undergoing Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

多因素分析显示仅血小板计数和L3骨骼肌指数预测新发肝性脑病,年龄和MELD-Na预测死亡,而肌肉减少症与L3骨骼肌指数未预测死亡;重复影像显示TIPSS后L3骨骼肌指数较基线显著改善。

要点

  • 肌肉减少症不应视为难治性腹水TIPSS禁忌,因其不增加死亡或新发肝性脑病风险。
  • TIPSS后L3骨骼肌指数可显著改善,提示肌肉减少症可能可逆。
  • 新发肝性脑病仅由血小板计数和L3骨骼肌指数预测。

核心结论

  • 肌肉减少症不应被视为难治性腹水患者TIPSS插入的禁忌症,因为它与新发肝性脑病或死亡率增加无关。

主要发现

  • 57%的患者存在肌肉减少症,30%的患者发生新发肝性脑病,所有患者均无TIPSS前肝性脑病病史。
  • 多因素分析中,仅血小板计数和L3骨骼肌指数预测新发肝性脑病。
  • 多因素分析中,年龄和MELD-Na预测死亡率,而L3骨骼肌指数和肌肉减少症未预测死亡率。
  • 在重复影像的患者中,TIPSS后L3骨骼肌指数较基线显著改善。

关键数值与推荐

  • 多因素分析显示血小板计数和L3骨骼肌指数预测新发肝性脑病,年龄和MELD-Na预测死亡率。

临床怎么用

  • 对于因难治性腹水考虑TIPSS的患者,肌肉减少症不应作为排除标准,因其不增加死亡或新发肝性脑病风险。
  • TIPSS后肌肉减少症可能改善,提示术后营养或肌肉状态监测可能有益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The impact of sarcopenia in patients undergoing transjugular intrahepatic portosystemic shunt (TIPSS) insertion for refractory ascites is unknown. METHODS: All adult patients who underwent TIPSS insertion for refractory ascites between 2010 and 2018 were included. Skeletal muscle index at L3 was used to determine sarcopenia status. RESULTS: One hundred seven patients were followed for 14.2 months. Sarcopenia was present in 57% of patients. No patient had history of pre-TIPSS hepatic encephalopathy (HE). De novo HE occurred in 30% of patients. On multivariate analysis, only platelet count and L3-SMI predicted de novo HE. On multivariate analysis, age and model for end-stage liver disease with sodium predicted mortality, whereas L3-SMI and sarcopenia did not. In patients with repeat imaging, L3-SMI improved significantly post-TIPSS compared with baseline. DISCUSSION: Sarcopenia should not be considered as a contraindication to TIPSS insertion in refractory ascites because it is not associated with de novo HE or increased mortality.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Benmassaoud A, Roccarina D, Arico F, et al. Sarcopenia Does Not Worsen Survival in Patients With Cirrhosis Undergoing Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites. Am J Gastroenterol. 2020. PMID: 33156111. doi:10.14309/ajg.0000000000000959

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。